Vincenzo Sucato

Dr. Vincenzo Sucato


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Journal of Cardiovascular Medicine
Verified
Journal Article
Open access
AMAnna V. Mattioli
Anna V. Mattioli
Pasquale PalmieroPasquale Palmiero
Pasquale Palmiero
OMOlivia Manfrini
Olivia Manfrini
PPPaolo E. Puddu
Paolo E. Puddu
SNSavina Nodari
Savina Nodari
MCMarco M. Ciccone
Marco M. Ciccone
Cardiovascular disease (CVD) accounts for more than 17 million deaths per year worldwide. It has been estimated that the influence of lifestyle on CVD mortality amounts to 13.7% for smoking, 13.2% for poor diet, and 12% for inactive lifestyle. These results deeply impact both the healthy status of individuals and their skills in working. The impact of CVD on productivity loss accounts for the 24% in total costs for CVD management. Mediterranean diet (MedD) can positively impact on natural history of CVD. It is characterized by a relatively high consumption of inexpensive and genuine food such as cereals, vegetables, legumes, nuts, fish, fresh fruits, and olive oil as the principal source of fat, low meat consumption and low-to-moderate consumption of milk, dairy products, and wine. Its effects on cardiovascular health are related to the significant improvements in arterial stiffness. Peripheral artery disease, coronary artery disease, and chronic heart failure are all positively influenced by the MedD. Furthermore, MedD lowers the risk of sudden cardiac death due to arrhythmias. The present narrative review aims to analyze the effects of MedD on CVD.

19 September 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
CMCristina Madaudo
Cristina Madaudo
GBGiada Bono
Giada Bono
AOAntonella Ortello
Antonella Ortello
GAGiuseppe Astuti
Giuseppe Astuti
Giulia MingoiaGiulia Mingoia
Giulia Mingoia
Vincenzo SucatoVincenzo Sucato
Vincenzo Sucato
High-density lipoprotein (HDL) cholesterol is traditionally viewed as protective against cardiovascular disease (CVD). However, emerging evidence reveals that dysfunctional HDL, characterized by impaired reverse cholesterol transport (RCT), reduced anti-inflammatory and antioxidant activities and increased endothelial dysfunction, which can contribute to coronary artery disease (CAD). Dysfunctional HDL, resulting from oxidative modifications of Apolipoprotein A-1 (Apo A-1) and enzyme inactivation, fails to effectively remove cholesterol from peripheral tissues and may promote inflammation and atherosclerosis. Genetic mutations affecting HDL metabolism further complicate its role in cardiovascular health. Studies have shown that conventional therapies aimed at raising HDL-C levels do not necessarily reduce cardiovascular events, highlighting the need for new approaches that improve HDL functionality. Therapeutic strategies such as Apo A-1 mimetic peptides, reconstituted HDL infusions, and drugs targeting specific HDL metabolic pathways are being explored. Additionally, weight loss, statin therapy, and niacin have shown potential in enhancing HDL function. The pathophysiology of dysfunctional HDL involves complex mechanisms, including oxidative stress, inflammation, and genetic mutations, which alter its structure and function, diminishing its cardioprotective effects. New functional assays, such as the cholesterol efflux capacity (CEC) and HDL inflammatory index, provide more accurate predictions of cardiovascular risk by assessing HDL quality rather than quantity. As research progresses, the focus is shifting towards therapeutic strategies that enhance HDL function and address the root causes of its dysfunction, offering a more effective approach to reducing cardiovascular risk and preventing CAD.

1 May 2021 in Journal of Cardiology
Verified
Journal Article
Closed access
Vincenzo SucatoVincenzo Sucato
Vincenzo Sucato
GTGabriella Testa
Gabriella Testa
SPSebastiano Puglisi
Sebastiano Puglisi
SESalvatore Evola
Salvatore Evola
AGAlfredo Ruggero Galassi
Alfredo Ruggero Galassi
GNGiuseppina Novo
Giuseppina Novo

29 April 2022 in Current Problems in Cardiology
Verified
Journal Article
Closed access
Vincenzo SucatoVincenzo Sucato
Vincenzo Sucato
GCGiuseppe Coppola
Giuseppe Coppola
GMGirolamo Manno
Girolamo Manno
GVGiuseppe Vadalà
Giuseppe Vadalà
GNGiuseppina Novo
Giuseppina Novo
AGAlfredo Ruggero Galassi
Alfredo Ruggero Galassi

24 September 2015 in Microcirculation
Verified
Journal Article
Closed access
PDF file
Vincenzo SucatoVincenzo Sucato
Vincenzo Sucato
SESalvatore Evola
Salvatore Evola
GNGiuseppina Novo
Giuseppina Novo
ASAngela Sansone
Angela Sansone
AQAngelo Quagliana
Angelo Quagliana
Salvatore NovoSalvatore Novo
Salvatore Novo

Verified
Journal Article
Open access
PDF file
APAntonio Luca Maria Parlati
Antonio Luca Maria Parlati
ENErmanno Nardi
Ermanno Nardi
Vincenzo SucatoVincenzo Sucato
Vincenzo Sucato
CMCristina Madaudo
Cristina Madaudo
GLGiulio Leo
Giulio Leo
PPPasquale Perrone-Filardi
Pasquale Perrone-Filardi
The growing prevalence in the diagnosis of INOCA (Ischemia with Non-Obstructive Coronary Arteries), ANOCA (Angina with Non-Obstructive Coronary Arteries), and MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) highlights the need to reassess their clinical relevance. Historically regarded as benign syndromes, emerging evidence suggests that these conditions may cause serious cardiovascular events and considerable long-term disability. Additionally, emerging studies suggest that non-obstructive coronary artery disease (CAD) may have a higher prevalence compared to traditional obstructive forms of CAD. This leads to the need to better clarify the underlying pathogenic mechanisms as well as the risk factors associated with these syndromes. This is precisely the aim of this review, which focuses on the complex and heterogeneous mechanisms underlying these syndromes as well as the associated risk factors. This review also sums up the diagnostic steps necessary to achieve an accurate diagnosis, along with the interventional and pharmacological approaches to be implemented in light of the latest evidence.